Fredrik Lehmann appointed CEO of EpiEndo
EpiEndo is pleased to welcome Fredrik Lehmann to our team as the new CEO of EpiEndo.
Fredrik has a PhD in Medicinal Chemistry from the University of Gothenburg and has vast experience from various drug projects in different phases of development. In addition to being the CEO of EpiEndo, Fredrik holds the position as Head of Research and CMC at Oncopeptides. Fredrik was the founder and CEO of OnTarget Chemistry in Upsala until it was acquired by Recipharm in 2015. Our compounds were developed and built at OnTarget Chemistry by Fredrik in co-operation with EpiEndo’s founder and now former CEO, Friðrik Rúnar Garðarsson, who will now take a seat at the Board of Directors and continue his good work for EpiEndo as an active Board Member.